Published in Adv Ther on June 04, 2014
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet (2013) 12.44
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med (2007) 10.87
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost (1993) 7.92
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet (2006) 5.11
Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol (2011) 4.98
Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet (2011) 4.78
Meta-analysis: effect of patient self-testing and self-management of long-term anticoagulation on major clinical outcomes. Ann Intern Med (2011) 3.53
Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost (2011) 2.35
Self-monitoring and self-management of oral anticoagulation. Cochrane Database Syst Rev (2010) 2.32
Optimal level of oral anticoagulant therapy for the prevention of arterial thrombosis in patients with mechanical heart valve prostheses, atrial fibrillation, or myocardial infarction: a prospective study of 4202 patients. Arch Intern Med (2009) 2.16
Atrial fibrillation prevalence revisited. J Intern Med (2013) 1.84
Precision and accuracy of point-of-care testing coagulometers used for self-testing and self-management of oral anticoagulation therapy. J Thromb Haemost (2012) 1.83
Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost (2010) 1.68
Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA). Circ Cardiovasc Qual Outcomes (2010) 1.50
Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res (2008) 1.47
Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-Analysis of Subgroups. Thrombosis (2013) 1.20
Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation. Thromb Res (2011) 0.98
Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. PLoS One (2012) 0.96
Results of the first randomized French study evaluating self-testing of the International Normalized Ratio. J Heart Valve Dis (2011) 0.88
A randomized trial comparing INR monitoring devices in patients with anticoagulation self-management: evaluation of a novel error-grid approach. J Thromb Thrombolysis (2007) 0.87
The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes (2011) 0.86
INR control calculation: comparison of Dutch and international methods. Neth J Med (2013) 0.81
Is home monitoring of international normalised ratio safer than clinic-based monitoring? Interact Cardiovasc Thorac Surg (2012) 0.79
STABLE results: warfarin home monitoring achieves excellent INR control. Am J Manag Care (2014) 0.78
Anticoagulation control with daily low-dose vitamin k to reduce clinically adverse outcomes and international normalized ratio variability: a systematic review and meta-analysis. Pharmacotherapy (2013) 0.77
Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patients. Expert Opin Emerg Drugs (2013) 0.77
Adult Langerhans cell histiocytosis. Eur J Haematol (2006) 1.74
Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis (2006) 0.93
Effects of cardiac surgery on hemostasis. Transfus Med Rev (2006) 0.93
Thrombelastography for the monitoring of lipopolysaccharide induced activation of coagulation. Thromb Haemost (2006) 0.91
Systemic inflammatory response syndrome after extracorporeal circulation: a predictive algorithm for the patient at risk. Hellenic J Cardiol (2011) 0.87
Recombinant activated factor VII in the treatment of near-fatal bleeding during pediatric brain tumor surgery. Report of two cases and review of the literature. J Neurosurg (2006) 0.84
The heparins: all a nephrologist should know. Nephrol Dial Transplant (2005) 0.79
Indicators of acute and persistent renal damage in adult thrombotic microangiopathy. PLoS One (2012) 0.79
Functional von Willebrand Factor assays are not predictive for the absence of highest-molecular weight von Willebrand Factor multimers in patients with aortic-valve stenosis. Thromb Haemost (2005) 0.77
Aortic stenosis, von Willebrand factor, and bleeding. N Engl J Med (2003) 0.77
Platelet adhesion onto immobilized fibrinogen under arterial and venous in-vitro flow conditions does not significantly differ between men and women. Thromb J (2007) 0.75
High clotting factor activities and enhanced platelet-related haemostasis in a patient with recurrent episodes of thrombotic-thrombocytopenic purpura: additional risk factors for onset and recurrence? Nephrol Dial Transplant (2005) 0.75
Can We Close the Discussion on PFO-Closure? Hellenic J Cardiol (2015) 0.75
No evidence for involvement of prothrombotic platelet receptor polymorphisms in acute coronary stent thrombosis. Int J Cardiol (2007) 0.75
Induction of tolerance after combined immunosuppression and -adsorption in two patients with acquired haemophilia after severe haemorrhages controlled by sequential administration of rFVIIa and FEIBA. Thromb Haemost (2009) 0.75
Pharmacology and clinical use of recombinant activated factor seven in neurosciences. Neurocrit Care (2007) 0.75
The Heyde syndrome: proposal for a unifying concept explaining the association of aortic valve stenosis, gastrointestinal angiodysplasia and bleeding. Int J Cardiol (2006) 0.75
[66-year old female patient with vitreous and mucosal bleeding]. Dtsch Med Wochenschr (2016) 0.75
[Spontaneous coronary spasm as a rare cause of survived sudden cardiac death]. Med Klin (Munich) (2002) 0.75
No evidence for an association of AB0 blood group and manifestation of thrombotic microangiopathies. Int J Cardiol (2011) 0.75